荣泰健康(603579) - 2025 Q3 - 季度财报

Financial Performance - Total revenue for Q3 2025 was CNY 337,947,966.23, a decrease of 0.43% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 25,484,824.37, down 18.25% year-over-year[4] - Total profit for the period was CNY 20,750,906.45, reflecting a significant decline of 42.09% compared to the previous year[4] - The basic earnings per share for the quarter was CNY 0.14, a decrease of 22.22% from the same period last year[5] - Total operating revenue for the first three quarters of 2025 was CNY 1,148,150,857.84, a decrease of 1.4% compared to CNY 1,164,316,596.07 in the same period of 2024[19] - Net profit for the first three quarters of 2025 was CNY 110,868,486.23, down 22.4% from CNY 142,791,783.02 in the same period of 2024[20] - Basic earnings per share for the first three quarters of 2025 was CNY 0.63, down from CNY 0.82 in the same period of 2024[20] - The company reported a total comprehensive income of CNY 140,615,970.85 for the first three quarters of 2025, compared to CNY 135,035,506.78 in 2024[20] Assets and Liabilities - Total assets at the end of the period were CNY 3,347,963,775.30, a decrease of 10.53% from the end of the previous year[5] - The company’s total assets were RMB 3,347,963,775.30, compared to RMB 3,742,040,010.16 at the end of 2024, reflecting a reduction of approximately 11%[14] - The total liabilities decreased to CNY 596,424,189.86 from CNY 1,726,421,575.63 year-over-year[19] - Short-term borrowings decreased significantly to RMB 150,313,928.40 from RMB 426,604,575.77, a reduction of about 65%[14] - The company’s accounts payable decreased to RMB 268,874,782.26 from RMB 425,718,240.47, indicating a decline of approximately 37%[14] Equity and Shareholder Information - Shareholders' equity attributable to the parent company increased by 36.44% to CNY 2,747,982,971.64 due to the conversion of convertible bonds[5] - The total equity attributable to shareholders increased to CNY 2,747,982,971.64 from CNY 2,014,115,666.39 in the previous year[19] - The total number of common shareholders at the end of the reporting period was 15,470[10] - The company reported a total of 2,303,200 shares held in the repurchase account, representing 1.13% of total shares[13] Cash Flow - Operating cash flow net amount increased to ¥71,563,658.77 from a negative ¥17,455,309.47 year-over-year[23] - Investment activities generated a net cash flow of ¥191,321,888.68, a significant improvement from a negative ¥683,307,671.94 in the previous period[23] - Financing activities resulted in a net cash flow of -¥337,556,092.87, compared to a positive ¥131,630,988.42 last year[24] - Total cash and cash equivalents at the end of the period decreased to ¥424,289,289.40 from ¥807,660,357.48[24] - Cash inflow from operating activities totaled ¥1,375,989,761.70, up from ¥1,330,058,902.62[23] - Cash outflow from operating activities decreased to ¥1,304,426,102.93 from ¥1,347,514,212.09[23] - Cash inflow from investment activities was ¥3,696,254,298.41, compared to ¥2,729,995,915.95 previously[23] - Cash outflow from investment activities increased to ¥3,504,932,409.73 from ¥3,413,303,587.89[23] - Cash inflow from financing activities was ¥274,156,927.89, down from ¥378,935,396.42[24] - Cash outflow from financing activities rose to ¥611,713,020.76 from ¥247,304,408.00[24] Expenses - The company experienced increased sales promotion and R&D expenses, contributing to the decline in profits[8] - Total operating costs increased to CNY 1,091,080,657.84, up 6.2% from CNY 1,027,733,709.64 year-over-year[19] - Research and development expenses rose to CNY 70,139,092.89, an increase of 23% compared to CNY 57,007,658.80 in 2024[19] - The financial expenses for the first three quarters of 2025 were CNY 17,009,223.55, compared to a gain of CNY 8,609,589.47 in the same period of 2024[19] Non-Recurring Items - Non-recurring gains and losses totaled CNY 15,866,802.50 for the quarter, with significant contributions from government subsidies and asset disposals[7]